Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
Urun Y, Yasar HA, Turna H, Esin E, Sedef AM, Alkan A, Oksuzoglu B, Ozdemir N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akman T, Akbulut H, Celik I, Abalı H.
Urun Y, et al. Among authors: oksuzoglu b.
J Oncol Pharm Pract. 2019 Oct;25(7):1658-1664. doi: 10.1177/1078155218805539. Epub 2018 Nov 6.
J Oncol Pharm Pract. 2019.
PMID: 30400750